Patent ID: 11965031
Assignee: BRISTOL-MYERS SQUIBB COMPANY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for treating a subject afflicted with a tumor comprising administering to the subject in need thereof
an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“anti-PD-1 antibody”) at a dose of about 200 mg or about 240 mg in combination with varlilumab at a dose of 3 mg/kg;
wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, MEDI0680, and BGB-A317.